Resistance of dialyzed patients to erythropoietin  by Alves, Michelle Teodoro et al.
rev bras hematol hemoter. 2 0 1 5;3  7(3):190–197
www.rbhh.org
Revista Brasileira de Hematologia e Hemoterapia
Brazilian Journal of Hematology and Hemotherapy
Update article
Resistance  of  dialyzed  patients  to erythropoietin
Michelle Teodoro Alvesa, Sandra Simone Vilac¸ab, Maria das Grac¸as Carvalhoa,
Ana  Paula Fernandesa, Luci Maria Sant’Ana Dussea, Karina Braga Gomesa,∗
a Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil
b Hospital Felício Rocho, Belo Horizonte, MG, Brazil
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 23 July 2014
Accepted 24 November 2014
Available online 17 February 2015
Keywords:
Dialysis
Erythropoietin
Iron
a  b  s  t  r  a  c  t
Resistance to recombinant human erythropoietin is a common condition in dialyzed
patients with chronic kidney disease and is associated with more hospitalizations, increased
mortality and frequent blood transfusions. The main cause of hyporesponsiveness to recom-
binant human erythropoietin in these patients is iron deﬁciency. However, a high proportion
of  patients does not respond to treatment, even to the use of intravenous iron, which indi-
cates the presence of other important causes of resistance. In addition to the iron deﬁciency,
the  most common causes of resistance include inﬂammation, infection, malnutrition, inad-
equate dialysis, and hyperparathyroidism, although other factors may be associated. In the
presence of adequate iron stores, other causes should be investigated and treated appropri-
ately.©  2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.
ever, despite rHuEPO and intravenous iron in the majority ofIntroduction
Chronic kidney disease (CKD) is considered a public health
problem worldwide with high incidence and prevalence rates.1
In end-stage renal disease (ESRD), renal function must be
replaced by dialysis or renal transplantation.2 In Brazil, the
number of patients on dialysis has increased gradually over
the years. According to the Sociedade Brasileira de Nefrologia
(SBN), 42,695 and 100,397 patients were under dialysis in 2000
and 2013, respectively.3Anemia is one of the most frequent early complications
of CKD.4 The main cause is erythropoietin (EPO) deﬁciency
due to impaired kidney function. However, other causes
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reserved.should be considered when the severity of anemia is incon-
sistent with the decrease in renal function; when there
is evidence of iron deﬁciency or matching decreases in
hemoglobin, leukopenia and/or thrombocytopenia are also
found.5
The treatment of anemia in CKD patients usually involves
the use of recombinant human erythropoietin (rHuEPO). The
main cause of rHuEPO treatment failure is the loss or low
iron availability.6 The prevalence of iron deﬁciency is very
common in CKD, affecting as many  as 50% of patients.7 How-01 Belo Horizonte, MG, Brazil.
patients, the prevalence of anemia reaches 34% in Brazil.8 This
indicates the existence of other important factors related to
rHuEPO resistance.
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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Table 1 – Deﬁnition of anemia and hemoglobin target in CKD patients.
EBPG 2004 NKF/KDOQI
2006/2007
ERBP: anemia group
position 2008
KDIGO 2012
Deﬁnition of anemia
Females <11.5 g/dL <12 g/dL <12 g/dL <12.0 g/dL
Males <13.5 g/dL
<12 g/dL aged
>70 years
<13.5  g/dL <13.5 g/dL <13.0 g/dL
Hemoglobin target >11 g/dL
>14 g/dL not
desirable
(>12 g/dL not
desirable in
CVD)
Generally
11–12 g/dL,
not to exceed
13 g/dL
Generally 11–12 g/dL,
not to exceed 13 g/dL
Generally
≤11.5 g/dL,
not to exceed
13 g/dL
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iEBPG: European Best Practice Guidelines; NKF/KDOQI: National Kidne
Renal Best Practice; Kidney Disease: KDIGO: Improving Global Outcom
The deﬁnition of anemia in CKD patients has changed with
ome guidelines being produced over the last few years. In
004 the Revised European Best Practice Guidelines (EBPG) on
nemia deﬁned low hemoglobin levels as values <11.5 g/dL
n adult females and <13.5 g/dL in adult males (<12 g/dL in
ver 70-year olds). Patients with CKD should maintain a
emoglobin level >11 g/dL (hematocrit >33%). In addition, lev-
ls >12 g/dL are not recommended for patients with severe
ardiovascular disease.9
An update of the 2006 National Kidney Foundation Kidney
isease Outcomes Quality Initiative (NKF/KDOQI) guidelines
n 2007 suggested that anemia is associated with hemoglobin
evels <13.5 g/dL in adult males and <12.0 g/dL in adult females.
n patients with CKD, hemoglobin should be between 11
nd 12 g/dL, however hemoglobin targets greater than 13 g/dL
ay increase the risk for serious adverse effects and are not
ecommended.5,10
The KDOQI modiﬁed the EBPG deﬁnition deﬁning anemia
n adult males as hemoglobin <13.5 g/dL regardless of age since
he decrease in hemoglobin levels among over 60-year-old
ales is frequently related to concurrent diseases. In addi-
ion, in adult females the hemoglobin target is 12 g/dL. The
uropean Renal Best Practice (ERBP) Work Group agrees with
he KDOQI deﬁnitions.11
Recently, the Kidney Disease: Improving Global Outcome
KDIGO) group deﬁned anemia in adults and children aged >15
ears with CKD when the hemoglobin levels are <13.0 g/dL in
ales and <12.0 g/dL in females.12 Table 1 shows the deﬁni-
ions of anemia and hemoglobin targets in CKD patients.
Although there is no consensus about the deﬁnition for
HuEPO resistance, the evaluation of resistance is recom-
ended if there is an increase ≥25% in erythropoietin dose
r <1 mg/dL gain in hemoglobin levels after 2–4 weeks of
reatment.13
According to the Brazilian Ministry of Health,14 rHuEPO
esistance is deﬁned as a persistent anemia (hemoglobin
10–12 g/dL) or the necessity of very high erythropoietin
oses of epoetin alfa (300 IU/kg/week subcutaneously or
50 IU/kg/week intravenously). Epoetin alfa should be initiated
t a dose of 50–100 IU/kg subcutaneously, one to three times a
eek. The initial goal of treatment is to achieve a rate of weekly
ncrease in hemoglobin levels of 0.3 g/dL. If after four weeks ofndation Kidney Disease Outcomes Quality Initiative; ERBP: European
VD: cardiovascular disease.
treatment, this response is not observed and the hemoglobin
remains below 11 g/dL, the dose should be increased by 25%.
However, after four weeks if the hemoglobin level is greater
than 13 g/dL, the drug should be suspended temporarily, since
the maintenance of higher hemoglobin levels is associated
with increased morbidity and mortality. The recommended
therapeutic target is to preserve hemoglobin levels from 11 to
12 g/dL or hematocrit from 33% to 36%.5
Anemia in CKD is usually normocytic and normochromic.
The characteristics of erythrocytes as determined by hema-
timetric indices, mean corpuscular volume (MCV), mean
corpuscular hemoglobin (MCH) and mean corpuscular
hemoglobin concentration (MCHC) can characterize the
etiology of anemia.15 In addition to hematimetric indices,
the laboratory investigation includes complete blood cell
count, reticulocyte count, serum iron, determination of the
transferrin saturation and serum ferritin, as well as occult
blood in stools and the levels of folic acid and vitamin B12.12,16
The biochemical markers of iron deﬁciency (serum iron,
ferritin, transferrin saturation and soluble transferrin recep-
tor – sTfR) have limited value in functional iron deﬁciency as
they are changed in several clinical conditions such as the
ones that evolve with rHuEPO therapy.17 However, reticulo-
cyte hemoglobin content (CHr or Ret-He) is a sensitive indirect
marker of iron deﬁciency, which reﬂects recent changes in
erythropoiesis.18 The measurement of CHr in peripheral blood
samples is useful for assessing the amount of functional iron
that was available in the bone marrow for new red blood
cell production over the previous 3–4 days.19 CHr may be a
more  sensitive marker of functional iron deﬁciency in patients
receiving erythropoietin therapy.20 It may also be an early indi-
cator of the effectiveness of iron replacement therapy.21
Thomas and Thomas22 presented a novel approach to func-
tional iron deﬁciency with the use of CHr and the percentage of
hypochromic erythrocytes (HYPO). Functional iron deﬁciency
was deﬁned as a CHr <28 pg and a HYPO <5% based on the lev-
els in healthy controls. Moreover, the sTfR-F index (sTfR/log
ferritin), which reﬂects the iron store status, can be used to
differentiate functional iron deﬁciency in states of iron deple-
tion and iron repletion. A diagnostic strategy combined CHr
and sTfR-F index to identify four major categories of iron deﬁ-
ciency: (1) iron repletion with normal erythropoiesis (CHr and
192  rev bras hematol hemoter.
Table 2 – Risk factors of resistance to recombinant
human erythropoietin.
Absolute or functional iron deﬁciency
Gastrointestinal blood loss
Hemolysis
Inﬂammation
Infection
Neoplastic diseases
Malnutrition
Folic acid and vitamin B12 deﬁciencies
Inadequate dialysis
Hyperparathyroidism
ACE inhibitors and ARBs
Anti-erythropoietin antibodies
Genetic polymorphisms
which evaluated the incidence and clinical signiﬁcance of B19ACE: angiotensin-converting enzyme; ARBs: angiotensin II type 1
receptor blockers.
sTfR-F index within appropriate reference values); (2) reduced
iron supply with still-normal erythropoiesis (CHr within ref-
erence values; increased sTfR-F index); (3) depletion of stores
and functional iron deﬁciency (reduced CHr; increased sTfR-
F index); and (4) functional iron deﬁciency in a state of iron
repletion (reduced CHr; sTfR-F index within reference values).
The strong association between anemia and cardiovascular
complications should be highlighted. The decrease in tissue
oxygenation causes tachycardia, vasodilation and increased
cardiac work and may cause left ventricular hypertrophy.23
The development and persistence of anemia in patients with
CKD are also associated with worse quality of life, reduced
exercise capacity, decreased mental agility and renal function
and increase the prevalence of hospitalization and mortality.13
The main causes of resistance to treatment with rHuEPO
(Table 2) in dialysis patients are discussed in this review.
Causes  of  resistance  to  treatment  with
recombinant  human  erythropoietin  in  patients
under  dialysis
Iron  deﬁciency
Iron deﬁciency or impairment of iron availability is the most
frequent cause of rHuEPO treatment resistance in patients
under dialysis.24,25
In these patients, the deﬁciency or reduction of total iron
stores can occur due to an increase in demand of this nutrient
during the production of red blood cells in the bone marrow.
This absolute iron deﬁciency may also be related to the dial-
ysis procedure, which promotes premature destruction of red
blood cells (hemolysis), but also due to gastrointestinal bleed-
ing, or frequent laboratory blood tests and surgeries, which
patients can be submitted to.26
In functional iron deﬁciency, suitable stores of this nutrient
can be observed, but the mobilization of iron to the blood-
stream is insufﬁcient to reach the demand of the erythroid
marrow. This condition is common in inﬂammatory states due
to the cytokines that block the release of iron from deposits.27
Iron deﬁciency anemia is characterized by microcytosis
and hypochromia and a careful microscopic examination of 2 0 1 5;3  7(3):190–197
erythrocytes may lead to suspicion of iron deﬁciency. Fur-
thermore, transferrin saturation and serum ferritin levels may
help to distinguish between conditions associated with deﬁ-
ciency or impairment in the availability of iron.5
Hepcidin, a small peptide synthesized mainly in
hepatocytes, is the central regulator of systemic iron
homeostasis.28,29 Hepcidin binds to ferroportin, an iron
transporter present on cells of the intestinal duodenum,
macrophages, and cells of the placenta, and regulates iron
release to the plasma. When hepcidin concentrations are
low, molecules of ferroportin are exposed on the plasmatic
membrane and release iron. When hepcidin levels increase,
hepcidin binds to ferroportin inducing its internalization and
degradation, thereby leading to reductions in iron release.30,31
Hepcidin concentration in turn is regulated by iron,
erythropoietic activity and inﬂammation.32 IL-6 induces hypo-
ferremia during inﬂammation by inducing the synthesis of
hepcidin caused by decreases in serum iron and transferrin
saturation. In addition, this cytokine by itself rapidly induces
hypoferremia. Since the process of erythropoiesis is the largest
consumer of iron in the body, the decrease in iron supply
reduces hemoglobin synthesis and can lead to anemia.33
Hepcidin deﬁciency or resistance to hepcidin is asso-
ciated with iron overload in hereditary hemochromatosis,
iron-loading anemia, and hepatitis C. Hepcidin excess or ferro-
portin deﬁciency is the cause of iron-refractory iron deﬁciency
anemia, ferroportin disease, anemia of inﬂammation, CKDs,
and cancer.34
Chronic  inﬂammation  and  infection
The role of inﬂammation in the development of anemia in
patients with CKD should be highlighted. It is known that the
release of cytokines such as interferon-gamma (IFN-), tumor
necrosis factor alpha (TNF-),  interleukin 1 (IL-1) and inter-
leukin 6 (IL-6) can induce rHuEPO erythroid progenitor cell
resistance or impair the release of stored iron in the reticu-
loendothelial system for the production of hemoglobin.35–37
Infectious diseases may also be related to anemia resulting in
chronic inﬂammation.38
A relationship between cytomegalovirus (CMV) infection
and lack of response to rHuEPO has been associated to
increased production of proinﬂammatory cytokines such as
IFN- and TNF-.39,40 Betjes et al.41 showed an association
between CMV and low hemoglobin levels in patients with CKD
undergoing hemodialysis and high doses of rHuEPO.
Besides chronic inﬂammatory process, human parvovirus
B19 (B19) can also cause anemia due to infection and lysis
of erythroid precursors in the bone marrow.42,43 This infec-
tion may worsen in patients who have increased red blood
cell destruction, as observed in patients undergoing dialy-
sis treatment. Moreover, these patients are under increased
risk of contracting HIV infection through blood transfusion or
hemodialysis.44–47
Although some cases of B19 infection in patients under-
going dialysis have been reported, there are few studiesinfection in these patients.48–50 Generally, this viral infection
has been associated with transient aplastic crisis and unre-
sponsiveness to treatment with rHuEPO.46,51 However, several
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tudies have reported the occurrence of acquired pure red cell
plasia (PRCA) and severe transfusion-dependent anemia in
idney transplant patients infected by B19.48,52–55 PRCA is a
isorder characterized by anemia that leads to the almost
omplete absence of erythroid cells from precursors in the
one marrow but with normal production of granulocytes and
egakaryocytes. Besides B19 infection, which has tropism for
rythroid precursors in the bone marrow, other conditions that
esult in PRCA include the presence of autoantibodies directed
gainst red lineage progenitors, transient erythroblastopenia
n childhood, pregnancy, leukemia, infectious processes, tox-
ns, and the use of some drugs.56
ofactor  deﬁciency  and  malnutrition
n patients under dialysis, the main causes of protein energy
alnutrition include low intake of nutrients; muscle loss due
o increased protein catabolism and decrease in their syn-
hesis; insulin resistance; loss of nutrients by dialysis and
xidative stress.57 The inﬂammatory process is also a major
ause of protein energy malnutrition, which may occur in
3–51% of patients under hemodialysis.58
Malnutrition has been associated with resistance to treat-
ent with rHuEPO in patients under dialysis. Laboratory tests
how low percentages of transferrin saturation index, low
erum albumin concentrations and body mass index (BMI), but
igh levels of C-reactive protein (CRP) in these patients.59,60 In
ddition to be a marker of iron stores, ferritin may also be
ncreased in malnutrition.61
Deﬁciencies of folic acid and vitamin B12 may be associ-
ted with anemia and resistance to treatment with rHuEPO.
hus, when macrocytosis is detected, the levels of these
utrients should be evaluated.62 Besides the changes in ery-
hropoiesis, folic acid and vitamin B12 deﬁciencies can lead
o increases in homocysteine levels, which in turn is associ-
ted with an increased risk of cardiovascular complications in
enal patients.63,64
nadequate  dialysis
n patients with CKD, damage to erythrocytes can occur in the
resence of uremic toxins, which also inhibit the production
f EPO and erythropoiesis. Furthermore, the dialysis procedure
auses mechanical damage to erythrocytes, and leads to blood
oss.65,66
The inadequacy of the dialysis dose is an important cause
f anemia in patients under dialysis. In order to evaluate
hether the dialysis procedure is removing enough uremic
oxins, the patient’s blood is sampled at the start and at
he end of dialysis. The levels of urea in the two blood
amples are then compared. In the Kt/V method, the dia-
yzer urea clearance (K) is multiplied by dialysis time (t), and
he product divided by the patient’s urea distribution vol-
me  (V). According to the NKF/KDOQI guidelines for patients
nder hemodialysis, the Kt/V target is ≥1.3, and in patients
nder peritoneal dialysis the target is ≥1.7/week.67 A study
61y Gaweda et al. showed that patients with adequate dialy-
is assessed by Kt/V, require lower doses of rHuEPO. Although
he pathophysiological mechanism that links inadequate dial-
sis to the lack of response to rHuEPO is still not completely 1 5;3  7(3):190–197 193
understood, other factors such as inﬂammation and vascular
access complications may be associated with poorer response
to treatment.
The adequacy of the dose of dialysis is also related to a
decrease in costs, since patients with the best values of Kt/V
require smaller doses of rHuEPO.68
Hyperparathyroidism
Hyperparathyroidism, characterized by increased parathy-
roid hormone (PTH), is associated with lack of response to
treatment with rHuEPO due to endogenous EPO inhibition,
reduction of erythroid precursors in the bone marrow and
erythrocyte survival. This hormone is also associated to the
induction of bone marrow ﬁbrosis.60,69,70
According to the NKF/KDOQI,71 PTH levels between 150
and 300 pg/mL are desirable in patients undergoing dial-
ysis. However, the threshold at which PTH levels could
affect the response to rHuEPO remains unclear. Rao et al.72
demonstrated that patients who responded to treatment with
rHuEPO had lower PTH levels (around 266 ± 322 pg/mL) com-
pared with those who did not respond to treatment, with
mean levels of 800 ± 248 pg/mL. Another study by Gaweda
et al.61 demonstrated that PTH levels of 300, 600 and 900 pg/mL
were associated with approximately 90%, 79% and 67% of the
maximum response to treatment with rHuEPO, respectively.
Angiotensin-converting  enzyme  inhibitors  and
angiotensin  II  type  1  receptor  blockers
The renin–angiotensin system was previously only thought
to affect the cardiovascular system. However, this system
plays also an important role in hematopoiesis which explains
the reduction in hematocrit levels or anemia as a side effect
of treatment using angiotensin-converting enzyme inhibitors
(ACE inhibitors) and angiotensin II type 1 receptor blockers
(ARBs).73,74
The ACE, which plays a central role in blood pressure
control system,75 is also responsible for the hydrolysis of
acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), a tetrapeptide
which naturally occurs in many  body tissues. The phys-
iological AcSDKP is a negative regulator of erythropoiesis
that inhibits the entry of hematopoietic stem cells in the S
phase of the cell cycle, keeping them in phase G0.76,77 Stud-
ies have shown that the use of ACE inhibitors is associated
with increased plasma concentrations of this tetrapeptide.
Thus, patients taking antihypertensive ACE inhibitors may
be resistant to treatment with rHuEPO.78,79 The lack of
angiotensin II production, due to an interruption of the
renin–angiotensin system, is a direct cause of anemia, indicat-
ing that angiotensin II regulates hematopoiesis.80 Angiotensin
II acts as a growth factor and directly stimulates prolifera-
tion of erythroid progenitors in the bone marrow. Additionally,
angiotensin II enhances EPO secretion, which results in
increased red blood cell mass.73
Decreases in hemoglobin levels occur in adults with CKD
81,82after therapy with ACE inhibitors and/or ARBs. These
drugs have been associated with a dose-dependent decrease
in hematocrit and anemia and should be considered in the
differential diagnosis of anemia in patients with a variety of
oter.
r
http://www.sbn.org.br/pdf/censo 2013-14-05.pdf [cited194  rev bras hematol hem
illnesses including renal transplantation, decreased kidney
function and heart failure. Since this effect can be reversible,
the decision to decrease the dose or discontinue ACE inhibitors
or ARBs therapy should consider the severity of the clinical
condition and availability of alternative therapies.83
Anti-erythropoietin  antibodies
Although treatment with rHuEPO is well tolerated by most
patients, a small number produce antibodies that can neu-
tralize either endogenous EPO and recombinant proteins.84
Most cases of antibody production have been associated
with the formulation of epoetin alfa when administered
subcutaneously.85
In some cases, the anti-erythropoietin (anti-EPO) anti-
body production can lead to development of serious PRCA
and transfusion-dependent anemia.86–88 Recent studies have
shown that anti-EPO antibody-mediated PRCA is a rare but
important adverse effect in patients with CKD who take
rHuEPO.89–91
According to the National Guidelines published by Brazil-
ian Ministry of Health, PRCA should be evaluated in patients
receiving epoetin alfa over at least four weeks that develop: (1)
a drop in hemoglobin levels equal to or greater than 0.5 g/dL
per week, in the absence of transfusions, and requirement of at
least one red blood cell unit per week to maintain hemoglobin
levels; (2) normal leukocyte and platelet counts; (3) absolute
reticulocyte count <10 × 103/L.92 Treatment recommenda-
tions for patients with PRCA induced by erythropoiesis
stimulating agents (ESA) are: (1) discontinuation of ESA; (2) cor-
rection of anemia by blood transfusion, if necessary; (3) kidney
transplant and (4) introduction of immunosuppressive ther-
apy starting with cyclosporine A alone or in combination with
corticosteroids or corticosteroids with cyclophosphamide.85,86
Diagnostic conﬁrmation of PRCA induced by anti-EPO anti-
bodies should include the antibody laboratory detection and
a bone marrow examination that shows the absence of ery-
throid lineage precursors.93 However, to date, there is no
consensus about the method of choice for the detection of
these antibodies, since the different methods have advantages
and disadvantages.87 Moreover, no commercial laboratory kit
is available for the detection of anti-EPO antibodies in the clin-
ical practice.89
Genetic  polymorphisms  and  the  EPO  receptor
Some genetic polymorphisms may result in individual
response variations to rHuEPO. Jeong et al.94 investigated
the association between the interleukin 1B (IL-1B) gene and
ACE gene polymorphisms and erythropoietin resistance index
(RI-EPO) in patients undergoing hemodialysis. Associations
between the presence of the IL-1B-511C/C and ACE D/D geno-
types with lower RI-EPO were identiﬁed, indicating that these
polymorphisms may be useful genetic markers in assessing
the required dose of rHuEPO in patients undergoing hemodial-
ysis.It is known that endogenous and recombinant EPO stimu-
lates erythropoiesis by binding to the EpoR receptor.95,96 An
mRNA  alternative splicing can give rise to the soluble form of
the receptor (sEpoR) which lacks the transmembrane domain. 2 0 1 5;3  7(3):190–197
sEpoR has a higher afﬁnity for EPO and acts as a potent antago-
nist of the hormone, which can lead to resistance to treatment
with rHuEPO. Therefore, high levels of sEpoR may be associ-
ated with administration of high doses of rHuEPO.97,98
Conclusion
The main cause of inadequate response to treatment with
rHuEPO is iron deﬁciency. However, several other factors may
be associated with this resistance in patients with CKD on
dialysis in the presence of adequate iron stores, and must be
investigated including: inﬂammation, infection, malnutrition,
inadequate dialysis and hyperparathyroidism. In addition, B19
infection, anti-EPO antibody production, and the presence of
polymorphisms have been identiﬁed as possible causes of
resistance to rHuEPO in dialysis patients. However, other stud-
ies in the Brazilian population, which has its own genetic
characteristics, with a larger sample size should be performed
to validate these factors.
Finally, as the main reason for poor response to the use of
rHuEPO is iron deﬁciency, which causes changes in the size
and color of red blood cells, the importance of monitoring
patients under dialysis through a simple blood test should
be emphasized, as this may reveal morphological changes
such as microcytosis and hypochromia consequent to the deﬁ-
ciency of this nutrient. On the other hand, deﬁciencies of folic
acid and/or vitamin B12 also lead to clinically signiﬁcant mor-
phological changes in red blood cells, such as macrocytosis.
Detection of morphological changes of red blood cells may
inﬂuence proper supplementation with the adequate nutrient
bringing beneﬁts to patients under hemodialysis by properly
correcting the anemia.
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